Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

21P - Analysis of germline variants in the immune response-related genes in BRCA1 mutation carriers: Possible modifying effect on age-dependent BRCA1 penetrance

Date

16 Sep 2021

Session

ePoster Display

Presenters

Ekaterina Kuligina

Citation

Annals of Oncology (2021) 32 (suppl_5): S361-S375. 10.1016/annonc/annonc684

Authors

E.S. Kuligina1, A.A. Romanko1, E.N. Suspitsin2, A.V. Tumakova3, A.S. Martianov1, I.V. Bizin1, J. Gorgul3, G.A. Yanus1, A. Kashyap4, C. Cybulski4, A. Jakubowska4, J. Lubiński4, E.N. Imyanitov5

Author affiliations

  • 1 Department Of Tumor Growth Biology, N.N. Petrov Institute of Oncology, 197758 - Saint-Petersburg/RU
  • 2 General And Molecular Medical Genetics, St. Petersburg Pediatric Medical University, 194100 - St. Petersburg/RU
  • 3 General And Molecular Medical Genetics, St. Petersburg Pediatric Medical University, 194100 - Saint Petersburg/RU
  • 4 Department Of Genetics And Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 70-204 - Szczecin/PL
  • 5 Department Of Tumor Growth Biology, N.N. Petrov National Medical Research Center of Oncology, 197758 - Saint-Petersburg/RU
More

Abstract 21P

Background

Most female carriers of germline BRCA1 mutation develop breast/ovarian cancer during the lifetime. However, the penetrance of BRCA1 pathogenic variants does not reach 100%, and the age of BRCA1-associated breast cancer (BC) onset varies widely. BRCA1-driven tumors are chromosomally unstable and may have excessive antigenicity. We hypothesized that hereditary variations in immune response pathways may contribute to the variability of BRCA1 penetrance. We evaluated whether genetic variations in the immune response-related genes contribute to this heterogeneity.

Methods

The entire coding sequence of 353 immune response genes was analyzed by NGS in 54 young (<39 y.o.) and 59 senior (>57 y.o.) BRCA1-mutated BC patients. Newly identified candidate variants were genotyped in the extended study, which included 185 young and 167 senior BC Slavic patients affected by BRCA1-driven BC.

Results

NGS analysis identified 54 allelic variants with gnomAD frequency <5% and a CADD-score of at least>/= 25, which were found exclusively either in young or in senior patients. The prevalence of 26 top candidates was analyzed in the extension study. The known pathogenic variant in the perforin gene (PRF1 p.Ala91Val) was significantly overrepresented in young BC patients compared with senior women (20 /carriers from 239 (8.4%) vs. 8/226 (3.5%), p = 0.032). PRF1 p.Ala91Val heterozygosity was associated with significant elevation of the risk of acquiring BC before the age of 39 years as compared to the BRCA1 mutation carriers with the wild-type PRF genotype [OR = 2.49, 95% CI: 1.073 - 5.771, p = 0.034].

Conclusions

Perforin is one of the principal cytotoxic proteins responsible for cell lysis mediated by T-lymphocytes and NK cells. PRF1 p.Ala91Val heterozygosity is known to be associated with subclinical symptoms of immunodeficiency. This study suggests that the PRF1 p.Ala91Val substitution may compromise antitumor immune response and support the development of tumors in BRCA1 carriers. This study revealed that the inherited haploinsufficiency of immunodeficiency-related gene PRF1 caused by pathogenic missense p.Ala91Val may increase the risk of early breast cancer manifestation in BRCA1 mutation carriers.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

RSF grant #19-15-00207

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings